2seventy bio, Inc.

NasdaqGS:TSVT Voorraadrapport

Marktkapitalisatie: US$163.0m

2seventy bio Beheer

Beheer criteriumcontroles 0/4

De CEO 2seventy bio is Chip Baird, benoemd in Apr2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.93M, bestaande uit 17.7% salaris en 82.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde $ 187.75K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.6 jaar en 1.2 jaar.

Belangrijke informatie

Chip Baird

Algemeen directeur

US$2.9m

Totale compensatie

Percentage CEO-salaris17.7%
Dienstverband CEOless than a year
Eigendom CEO0.1%
Management gemiddelde ambtstermijnless than a year
Gemiddelde ambtstermijn bestuur1.2yrs

Recente managementupdates

Recent updates

Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report

Nov 15
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

Oct 03
There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Jul 04
2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

May 11
Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Apr 03

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

Mar 07
These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Feb 06
2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

Jan 17
Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Dec 13
2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

May 05
Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

Mar 21
Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 19
2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

Oct 04
We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

2seventy Bio: This Spinoff In The CAR-T Space Is Attractive

Sep 08

2seventy bio Prospects

Aug 23

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Aug 12
Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Analyse CEO-vergoeding

Hoe is Chip Baird's beloning veranderd ten opzichte van 2seventy bio's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$95m

Jun 30 2024n/an/a

-US$156m

Mar 31 2024n/an/a

-US$223m

Dec 31 2023US$3mUS$518k

-US$218m

Sep 30 2023n/an/a

-US$184m

Jun 30 2023n/an/a

-US$180m

Mar 31 2023n/an/a

-US$215m

Dec 31 2022n/an/a

-US$254m

Sep 30 2022n/an/a

-US$292m

Jun 30 2022n/an/a

-US$284m

Mar 31 2022n/an/a

-US$291m

Dec 31 2021US$2mUS$491k

-US$292m

Sep 30 2021n/an/a

-US$308m

Jun 30 2021n/an/a

-US$320m

Mar 31 2021n/an/a

-US$222m

Dec 31 2020US$2mUS$475k

-US$120m

Compensatie versus markt: De totale vergoeding ($USD 2.93M ) Chip } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Chip is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chip Baird (52 yo)

less than a year

Tenure

US$2,927,118

Compensatie

Mr. William D. Baird III, also known as Chip, serves as Chief Executive Officer, President and Director of 2seventy bio, Inc. since April 1, 2024. He was Principal Financial Officer and Principal Accountin...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
William Baird
CEO, President & Directorless than a yearUS$2.93m0.12%
$ 187.7k
Victoria Eatwell
Chief Financial Officerless than a yeargeen gegevens0.66%
$ 1.1m
Jessica Snow
Senior VP of Quality and Head of Operationsless than a yeargeen gegevens0.30%
$ 492.2k
Anna Truppel-Hartmann
Chief Medical Officerless than a yeargeen gegevensgeen gegevens

0.6yrs

Gemiddelde duur

45yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TSVT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.6 jaar), wat duidt op een nieuw team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
William Baird
CEO, President & Directorless than a yearUS$2.93m0.12%
$ 187.7k
Eli Casdin
Independent Directorless than a yeargeen gegevensgeen gegevens
Nick Leschly
Chairman of the Boardless than a yearUS$9.08m1.43%
$ 2.3m
Charles Newton
Independent Directorless than a yeargeen gegevensgeen gegevens
Marcela Maus
Independent Director3.1yrsUS$290.00k0.028%
$ 46.1k
Denice Torres
Lead Independent Director3.1yrsUS$304.00k0.038%
$ 61.7k
Sarah J. Glickman
Independent Director3.1yrsUS$303.00k0.028%
$ 46.1k
Wei Lin
Independent Director1.7yrsUS$622.05k0.019%
$ 30.8k

1.2yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TSVT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw bestuur.